drugset / Trial / NCT03293030
Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis
Phase 4
Completed
17 enrolled
University of California, San Francisco
Regeneron Pharmaceuticals · collabSanofi · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label study to examine the effect of dupilumab on the immunologic and genetic environment within atopic dermatitis skin lesions.
Timeline
- Start
- 2018-10-22
- Primary completion
- 2023-02-23
- Completion
- 2023-02-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dupilumab | Monoclonal antibody | — | — |